Business Wire

LivaNova Receives CE Mark for VNS Therapy SenTiva Generator and Next-Generation Programming System for Treatment of Epilepsy

Jaa

LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it received CE Mark for its Vagus Nerve Stimulation Therapy® (“VNS Therapy”) System comprised of the SenTiva® generator and next-generation Programming System for the treatment of patients with drug-resistant epilepsy (“DRE”). The Company received FDA approval for the full VNS Therapy System in October 2017.

The SenTiva generator offers the smallest and lightest responsive therapy with a number of new advanced features for the treatment of DRE. SenTiva is the only device of its size to include the AutoStim Mode, also known as Seizure Response Mode, which is designed to detect seizures and automatically deliver an extra dose of therapy. The generator is also designed to collect and log events including a patient’s body position and heart rate fluctuations.

The next-generation Programming System includes a small tablet and wireless programming wand compatible with the SenTiva generator and all LivaNova legacy VNS Therapy generators. When combined with SenTiva’s smart technology, the Programming System provides several advanced options and makes delivering treatment easier and more efficient through personalized patient-centric features.

“CE Mark combined with recent FDA approval for the SenTiva generator and Programming System advances VNS Therapy treatment for patients with drug-resistant epilepsy across the globe,” said Edward Andrle, LivaNova’s General Manager of its Neuromodulation business franchise. “Not only is the new VNS Therapy System simpler to use, making drug-resistant epilepsy treatment easier, the SenTiva generator and Programming System work together to allow physicians to confidently deliver proven results through customizable, smart technology. After a successful launch in the U.S., we look forward to seeing European patients benefit from our latest technology advancements.”

The new System’s features include:

  • Guided Programming – Advanced technology allows physicians to quickly and confidently deliver a proven treatment with one touch.
  • Scheduled Programming – Physicians can safely program multiple therapeutic steps in one office visit; the generator will then gradually and automatically increase therapy without the need for the patient to return to the physician. Scheduled programming can be very helpful, since many patients with epilepsy are not able to drive. This feature may also allow the patient to achieve a target dosage sooner.
  • Day-Night Programming – Physicians have unrivalled flexibility to customize therapy for when their patients need it at specific times, day or night.

The new features will help improve patients’ overall quality of life, make VNS Therapy easier to use and bring value to the healthcare system. Treatment with VNS Therapy can result in fewer seizures, shorter seizures and faster recovery; to date, it has been used by more than 100,000 patients globally.1

“SenTiva provides exciting advances in neuromodulation therapy for drug-resistant epilepsy. The smaller size and new programming features expand the range of patients we can treat,” said Dr. David McCormick, Clinical Lead for Paediatric Neurosciences at King’s College Hospital, London. “To that end, we are pleased to announce that the first SenTiva implant in a pediatric patient in Europe took place at King’s College Hospital in London.”

1. Data on file, LivaNova PLC, Houston, TX.

About VNS Therapy for Epilepsy

VNS Therapy is clinically proven safe and effective for the treatment of drug-resistant epilepsy for adults and children. VNS Therapy is designed to prevent seizures before they occur and stop them if they do. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects one in three people with epilepsy. For more information, visit www.VNSTherapy.co.uk

INTENDED USE/INDICATIONS – EU

The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to seizure medications.

Individual results may vary. Common side effects include hoarseness or changes in voice tone, prickling feeling in the skin, shortness of breath, sore throat and coughing. Visit http://en.eu.livanova.cyberonics.com/safety-information to view safety and full prescribing information.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs more than 4,500 employees, inclusive of approximately 900 employed by our CRM business franchise. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit www.livanova.com .

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe LivaNova’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this news release are based on information presently available to LivaNova and assumptions that LivaNova believes to be reasonable, but are inherently uncertain. As a result, LivaNova’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance or actions that may be taken by LivaNova and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond LivaNova’s control.

All information in this news release is as of the date of its release. LivaNova does not undertake or assume any obligation to update publicly any of the forward-looking statements in this news release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this news release.

Contact information

LivaNova PLC Investor Relations and Media
Karen King, +1 (281) 228-7262
Vice President, Investor Relations & Corporate Communications
or
Deanna Wilke, +1 (281) 727-2764
Director, Corporate Communications – Products and Therapies
corporate.communications@livanova.com
or
Melissa Rieger, +1 (412) 251-2172
Havas PR
melissa.rieger@havas.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

AGCO Focuses on Animal Welfare17.1.2019 13:00Tiedote

AGCO (NYSE: AGCO), a global leader in manufacturing and the distribution of agricultural equipment and solutions, today hosted its annual AGCO Berlin Summit. The international industry event aims to bring together decision-makers in politics, economy and society to share their experiences and discuss the future of the agricultural industry. Today’s ‘Feeding the World - The Future for Protein’ summit was focused on aspects of animal welfare in the context of modern agriculture, including the need for sustainable protein production to meet an increasing demand for protein-rich foods. The AGCO Berlin Summit is a joint initiative of AGCO and the new AGCO Agriculture Foundation. The AGCO Agriculture Foundation develops charitable initiatives to enhance global food security, sustainable agricultural development and positive economic impacts, particularly in developing countries. As in previous years, AGCO Finance and AGCO Fuse Technologies are sponsors of the 2019 AGCO Berlin Summit. "Whilst

Mr. Paul Bridwell Joins OpenGate Capital in Senior Operations Role for North America17.1.2019 11:00Tiedote

OpenGate Capital, a global private equity firm, announced that Mr. Paul Bridwell joined the firm on November 5th, 2018, as Managing Director to lead operations and portfolio management for the firm’s North American-based investments. Based in Los Angeles, Bridwell joins the OpenGate senior leadership team as a member of the firm’s Investment and Portfolio Committees. Bridwell is a tenured professional with 15 years of private equity experience and has a proven track record of delivering operating results leading to superior investor returns. He possesses solid leadership and organizational skills both as portfolio company CEO and as an operations leader developed through his tenure at two global, private equity firms. Prior to joining OpenGate, Bridwell was Partner and Managing Director – Head of Operations at a major private equity investment firm in New York City, where he established the firm’s first operations-focused group and developed a comprehensive operations approach compatib

Anywhere365 Introduces Web Agent for Microsoft Dynamics 36517.1.2019 10:00Tiedote

Workstreampeople, a global leader in contact center solutions for Skype for Business and Microsoft Teams, today announced the introduction of the Anywhere365 Web Agent for Microsoft Dynamics 365. Based on the Dynamics 365 Channel Integration Framework (CIF) the Web Agent is nested in the Dynamics 365 interface and provides users with Anywhere365’s omni-channel contact center functionality without having to move between applications. The Dynamics 365 client is automatically resized to accommodate the Web Agent ensuring none of the user interface is masked. Agents can receive, send, and automatically log calls, chats, emails and video all from within Dynamics 365, improving the efficiency and accuracy of customer interactions. From the Anywhere365 Web Agent, Dynamics 365 users can control media interactions and monitor real-time queue information. Integration with Microsoft Azure services provides automatic language detection and real-time translation of chat and voice interactions betwe

Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 201917.1.2019 09:30Tiedote

Regulatory News: Results of the first in-human study of a recombinant neurotoxin are being presented at the TOXINS International Conference in Copenhagen. Ipsen’s recombinant BoNT serotype E (rBoNT-E) was investigated in a phase I study that demonstrated its safety and tolerability profile in healthy volunteers1. The study also reported that it has a faster onset of action and a shorter duration of effect, as well as a quick time to peak activity, in comparison with established BoNT-A products. Further studies will be initiated to establish potential aesthetic and therapeutic uses of this investigational therapy. “The application of recombinant techniques to create novel botulinum toxin-based medicines with different onsets and durations of action, will potentially offer clinicians the flexibility to choose the most appropriate neurotoxin for each patient, which is not an option today,” said Philippe Picaut, Pharm. D., PhD, Senior Vice President Research & Development for the Neuroscie

NTT Communications to Expand Ecosystem for Interconnection of Major Data Centers in Japan17.1.2019 06:04Tiedote

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), announced today that it will expand the interconnection of its Nexcenter™ data centers in Tokyo and Osaka, Japan to enable client companies to connect with cloud and content services more flexibly than ever before. On a sequential basis from this month, NTT Com will begin directly connecting its ecosystem with three major internet exchanges (IXs) in Japan to enable clients to access services offered by these IXs and various NTT Com partner companies. Thereafter, NTT Com will continue to expand this ecosystem centered on NTT Com’s Nexcenter™ data centers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005908/en/ Expanding Interconnection (Graphic: Business Wire) As a DX Enabler™, NTT Com uses ICT to achieve digital transformation (DX) "Transform and create business" together with clien

Piraeus Bank Presents the Principles for Responsible Banking with the Governor of the Bank of Greece16.1.2019 21:21Tiedote

The Principles for Responsible Banking were presented today for the first time in Greece at an event organized by Piraeus Bank with Mr. Yannis Stournaras, the Governor of the Bank of Greece, as the keynote speaker. The event was organised as part of Piraeus Bank’s commitment to the United Nations Environment Programme Finance Initiative (UNEP FI). Piraeus is the only Greek bank to be a member of the global initiative, which includes twenty-eight banks from around the world, representing over USD 17 trillion in combined assets. Mr. Yannis Stournaras, the Governor of Bank of Greece, highlighted in his speech that the Bank of Greece fully supports the Principles for Responsible Banking and urges all of the banks to endorse the Principles and set ambitious targets. The Bank of Greece was one of the first central banks to become involved with the climate change issue, establishing the Climate Change Impacts Study Committee in 2009 and investing in one of the most significant Sustainable Dev

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme